Background Patients with transient ischemic attack (TIA) or minor stroke are at risk of
strokes. One of the precautionary measures to reduce risk of stroke in these patients is …

Management, and Avoidance) randomized trial, the combination of clopidogrel 75 mg/day
plus aspirin (dosage range 75 mg to 162 mg daily) was compared with aspirin alone in …

Antiplatelet therapy is a mainstay of secondary prevention of ischemic strokes. Recent
studies, such as Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) …

Background Clopidogrel was superior to aspirin in patients with previous manifestations of
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high …

Multiple randomized trials indicated that antiplatelet agents, including aspirin alone,
clopidogrel alone, and combined aspirin plus extended-release dipyridamole, can prevent …

Objective: Patients experiencing acute ischemic stroke or transient ischemic attack are
commonly treated with clopidogrel and/or aspirin (mono-and dual-antiplatelet therapy) to …

OBJECTIVE: To identify confounding factors that may explain the incoherence between
direct and indirect evidence in a published analysis comparing extended-release …

Background—The Clopidogrel in High-risk patients with Acute Non-disabling
Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel …

Antiplatelet therapy has shown consistent benefit in the prevention of secondary stroke. The
paucity of head‐to‐head studies of different antiplatelet regimens, assessment of …

This review addresses 2 fields: secondary prevention after cerebral ischaemia of cardiac
origin (CICO) and that after cerebral ischaemia of arterial origin (CIAO). The major trial after …